Chemotherapeutic Strategies in Brain Tumors

  • Soumen KhatuaEmail author


Brain tumors are the commonest solid tumor in children and chemotherapy remains an important treatment as a part of a multidisciplinary approach to treat these malignancies. Over the last two decades, cooperative groups have evaluated clinical trials geared to enhancing therapeutic efficacy and better understanding of the toxicity profile of conventional drugs. Recent molecular characterization of the genomic and epigenomic landscape of these tumors have resulted in an explosion of biological data, providing insights into the signaling pathway and paving the way to target druggable oncogenic drivers. This has ushered in an era of targeted therapy. Even with refinement of these strategies, challenges remain in the inability to comprehensively understand the mechanistic of drug resistance, and suboptimal drug delivery through the blood brain barrier (BBB). The ultimate therapeutic optimism will be achieved, if we are able to combine all these scientific discernments, and be able to depict the most effective chemotherapy and efficient delivery techniques for childhood brain tumors.


  1. Adamson P, Balis FM, Berg SL (2006) General principles of chemotherapy. In: Pizzo PA, Poplack DG (eds) Principles and practice of pediatric oncology. Lippincot, Williams and Wilkins, PhiladelphiaGoogle Scholar
  2. Agarwal S, Mittapalli RK, Zellmer DM, Gallardo JL, Donelson R, Seiler C, Decker SA, Santacruz KS, Pokorny JL, Sarkaria JN, Elmquist WF, Ohlfest JR (2012) Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents. Mol Cancer Ther 11(10):2183–2192. doi: 10.1158/1535-7163.MCT-12-0552 CrossRefPubMedPubMedCentralGoogle Scholar
  3. Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, Lazarus KH, Packer RJ, Prados M, Sposto R, Vezina G, Wisoff JH, Pollack IF (2012) Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol 30(21):2641–2647. doi: 10.1200/JCO.2011.36.6054 CrossRefPubMedPubMedCentralGoogle Scholar
  4. Avery RA, Hwang EI, Jakacki RI, Packer RJ (2014) Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol 132(1):111–114. doi: 10.1001/jamaophthalmol.2013.5819 CrossRefPubMedGoogle Scholar
  5. Baruchel S, Sharp JR, Bartels U, Hukin J, Odame I, Portwine C, Strother D, Fryer C, Halton J, Egorin MJ, Reis RM, Martinho O, Stempak D, Hawkins C, Gammon J, Bouffet E (2009) A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. Eur J Cancer 45(13):2352–2359. doi: 10.1016/j.ejca.2009.05.008 CrossRefPubMedGoogle Scholar
  6. Blaney SM, Boyett J, Friedman H, Gajjar A, Geyer R, Horowtiz M, Hunt D, Kieran M, Kun L, Packer R, Phillips P, Pollack IF, Prados M, Heideman R (2005) Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a Pediatric Brain Tumor Consortium study (PBTC-001). J Clin Oncol 23(3):525–531. doi: 10.1200/JCO.2005.06.544 CrossRefPubMedGoogle Scholar
  7. Bouffet E, Khelfaoui F, Philip I, Biron P, Brunat-Mentigny M, Philip T (1997) High-dose carmustine for high-grade gliomas in childhood. Cancer Chemother Pharmacol 39(4):376–379. doi: 10.1007/s002800050586 CrossRefPubMedGoogle Scholar
  8. Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S (2012) Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 30(12):1358–1363. doi: 10.1200/JCO.2011.34.5843 CrossRefPubMedGoogle Scholar
  9. Brantley EC, Benveniste EN (2008) Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 6(5):675–684. doi: 10.1158/1541-7786.MCR-07-2180 CrossRefPubMedGoogle Scholar
  10. Broniscer A, Baker SD, Wetmore C, Pai Panandiker AS, Huang J, Davidoff AM, Onar-Thomas A, Panetta JC, Chin TK, Merchant TE, Baker JN, Kaste SC, Gajjar A, Stewart CF (2013) Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res 19(11):3050–3058. doi: 10.1158/1078-0432.CCR-13-0306 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Bruce JN, Fine RL, Canoll P, Yun J, Kennedy BC, Rosenfeld SS, Sands SA, Surapaneni K, Lai R, Yanes CL, Bagiella E, DeLaPaz RL (2011) Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 69(6):1272–1279. ; discussion 1279–1280. doi: 10.1227/NEU.0b013e3182233e24 CrossRefPubMedPubMedCentralGoogle Scholar
  12. Cabanas R, Saurez G, Rios M, Alert J, Reyes A, Valdes J, Gonzalez MC, Pedrayes JL, Avila M, Herrera R, Infante M, Echevarria E, Moreno M, Luaces PL, Ramos TC (2013) Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience. mAbs 5(2):202–207. doi: 10.4161/mabs.22970 CrossRefPubMedPubMedCentralGoogle Scholar
  13. Cappellano AM, Senerchia AA, Adolfo F, Paiva PM, Pinho R, Covic A, Cavalheiro S, Saba N (2013) Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex. Childs Nerv Syst 29(12):2301–2305. doi: 10.1007/s00381-013-2170-0 CrossRefPubMedGoogle Scholar
  14. Cefalo G, Massimino M, Ruggiero A, Barone G, Ridola V, Spreafico F, Potepan P, Abate ME, Mascarin M, Garre ML, Perilongo G, Madon E, Colosimo C, Riccardi R (2014) Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. Neuro-Oncology 16(5):748–753. doi: 10.1093/neuonc/not320 CrossRefPubMedPubMedCentralGoogle Scholar
  15. Cheng Y, Zhang Y, Zhang L, Ren X, Huber-Keener KJ, Liu X, Zhou L, Liao J, Keihack H, Yan L, Rubin E, Yang JM (2012) MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther 11(1):154–164. doi: 10.1158/1535-7163.MCT-11-0606 CrossRefPubMedGoogle Scholar
  16. Chou PM, Barquin N, Gonzalez-Crussi F, Ridaura Sanz C, Tomita T, Reyes-Mugica M (1996) Ependymomas in children express the multidrug resistance gene: immunohistochemical and molecular biologic study. Pediatr Pathol Lab Med 16(4):551–561CrossRefPubMedGoogle Scholar
  17. da Silva NS, Cappellano AM, Diez B, Cavalheiro S, Gardner S, Wisoff J, Kellie S, Parker R, Garvin J, Finlay J (2010) Primary chemotherapy for intracranial germ cell tumors: results of the third international CNS germ cell tumor study. Pediatr Blood Cancer 54(3):377–383. doi: 10.1002/pbc.22381 CrossRefPubMedGoogle Scholar
  18. Dahlborg SA, Petrillo A, Crossen JR, Roman-Goldstein S, Doolittle ND, Fuller KH, Neuwelt EA (1998) The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J Sci Am 4(2):110–124PubMedGoogle Scholar
  19. de Bont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R (2008) Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective. Neuro-Oncology 10(6):1040–1060. doi: 10.1215/15228517-2008-059 CrossRefPubMedPubMedCentralGoogle Scholar
  20. Dhall G, Grodman H, Ji L, Sands S, Gardner S, Dunkel IJ, McCowage GB, Diez B, Allen JC, Gopalan A, Cornelius AS, Termuhlen A, Abromowitch M, Sposto R, Finlay JL (2008) Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols. Pediatr Blood Cancer 50(6):1169–1175. doi: 10.1002/pbc.21525 CrossRefPubMedGoogle Scholar
  21. Duffner PK, Krischer JP, Horowitz ME, Cohen ME, Burger PC, Friedman HS, Kun LE (1998) Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol 44(3):313–316. doi: 10.1002/ana.410440305 CrossRefPubMedGoogle Scholar
  22. Duffner PK, Horowitz ME, Krischer JP, Burger PC, Cohen ME, Sanford RA, Friedman HS, Kun LE (1999) The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro-Oncology 1(2):152–161CrossRefPubMedPubMedCentralGoogle Scholar
  23. Felix FH, de Araujo OL, da Trindade KM, Trompieri NM, Fontenele JB (2013) Survival of children with malignant brain tumors receiving valproate: a retrospective study. Childs Nerv Syst 29(2):195–197. doi: 10.1007/s00381-012-1997-0 CrossRefPubMedGoogle Scholar
  24. Ford J, Osborn C, Barton T, Bleehen NM (1998) A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer 34(11):1807–1811CrossRefPubMedGoogle Scholar
  25. Fujiwara T, Ogawa T, Irie K, Tsuchida T, Nagao S, Ohkawa M (1994) Intra-arterial chemotherapy for brain stem glioma: report of four cases. Neuroradiology 36(1):74–79CrossRefPubMedGoogle Scholar
  26. Gajjar A, Stewart CF, Ellison D, Curran T, Phillips P, Goldman S, Packer R, Kun L, Boyett J, Gilbertson R (2010) A phase I pharmacokinetic trial of Sonic Hedhehog (SHH) antagonist GDC-0499 in pediatric patients with recurrent or refractory medulloblastoma: a Pediatric Brain Tumor Consortium study (PBTC 25). J Clin Oncol 28(18 supplement):CRA9501CrossRefGoogle Scholar
  27. Garvin JH Jr, Selch MT, Holmes E, Berger MS, Finlay JL, Flannery A, Goldwein JW, Packer RJ, Rorke-Adams LB, Shiminski-Maher T, Sposto R, Stanley P, Tannous R, Pollack IF, Children’s Oncology G (2012) Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children’s Cancer Group protocol 9942: a report from the Children’s Oncology Group. Pediatr Blood Cancer 59(7):1183–1189. doi: 10.1002/pbc.24274 CrossRefPubMedGoogle Scholar
  28. Geoerger B, Aerts I, Casanova M, Chisholm J, Hargrave D, Leary S, Ashley DM, Bouffet E, MacDonald T, Hurh E, Jyotirmoy D, Kalambakas S, Dokyi D, Kieran M (2012) A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors. J Clin Oncol 30:9519Google Scholar
  29. Gerber NU, von Hoff K, Resch A, Ottensmeier H, Kwiecien R, Faldum A, Matuschek C, Hornung D, Bremer M, Benesch M, Pietsch T, Warmuth-Metz M, Kuehl J, Rutkowski S, Kortmann RD (2014) Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy. Int J Radiat Oncol Biol Phys 89(4):863–871. doi: 10.1016/j.ijrobp.2014.04.017 CrossRefPubMedGoogle Scholar
  30. Geyer JR, Zeltzer PM, Boyett JM, Rorke LB, Stanley P, Albright AL, Wisoff JH, Milstein JM, Allen JC, Finlay JL et al (1994) Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J Clin Oncol 12(8):1607–1615CrossRefPubMedGoogle Scholar
  31. Gnekow AK, Falkenstein F, von Hornstein S, Zwiener I, Berkefeld S, Bison B, Warmuth-Metz M, Driever PH, Soerensen N, Kortmann RD, Pietsch T, Faldum A (2012) Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro-Oncology 14(10):1265–1284. doi: 10.1093/neuonc/nos202 CrossRefPubMedPubMedCentralGoogle Scholar
  32. Goldie JH (2001) Drug resistance in cancer: a perspective. Cancer Metastasis Rev 20(1–2):63–68CrossRefPubMedGoogle Scholar
  33. Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Fouladi M, Kun LE (2014) Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas—a Pediatric Brain Tumor Consortium study. Neuro-Oncology 16(2):310–317. doi: 10.1093/neuonc/not154 CrossRefPubMedGoogle Scholar
  34. Haas-Kogan DA, Banerjee A, Poussaint TY, Kocak M, Prados MD, Geyer JR, Fouladi M, Broniscer A, Minturn JE, Pollack IF, Packer RJ, Boyett JM, Kun LE (2011) Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro-Oncology 13(3):298–306. doi: 10.1093/neuonc/noq202 CrossRefPubMedPubMedCentralGoogle Scholar
  35. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. doi: 10.1056/NEJMoa043331 CrossRefPubMedGoogle Scholar
  36. Hiesiger EM, Green SB, Shapiro WR, Burger PC, Selker RG, Mahaley MS Jr, Ransohoff J 2nd, VanGilder JC, Mealey J Jr, Robertson JT et al (1995) Results of a randomized trial comparing intra-arterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: brain tumor cooperative group trial 8420A. J Neuro-Oncol 25(2):143–154CrossRefGoogle Scholar
  37. Hori T, Muraoka K, Saito Y, Sasahara K, Inagaki H, Inoue Y, Adachi S, Anno Y (1987) Influence of modes of ACNU administration on tissue and blood drug concentration in malignant brain tumors. J Neurosurg 66(3):372–378. doi: 10.3171/jns.1987.66.3.0372 CrossRefPubMedGoogle Scholar
  38. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, Weigel B, Blaney SM (2013) A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children’s Oncology Group phase 1 consortium study. Pediatr Blood Cancer 60(9):1452–1457. doi: 10.1002/pbc.24541 CrossRefPubMedPubMedCentralGoogle Scholar
  39. Imbesi F, Marchioni E, Benericetti E, Zappoli F, Galli A, Corato M, Ceroni M (2006) A randomized phase III study: comparison between intravenous and intraarterial ACNU administration in newly diagnosed primary glioblastomas. Anticancer Res 26(1B):553–558PubMedGoogle Scholar
  40. Jahnke K, Kraemer DF, Knight KR, Fortin D, Bell S, Doolittle ND, Muldoon LL, Neuwelt EA (2008) Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. Cancer 112(3):581–588. doi: 10.1002/cncr.23221 CrossRefPubMedGoogle Scholar
  41. Jakacki RI, Burger PC, Kocak M, Boyett JM, Goldwein J, Mehta M, Packer RJ, Tarbell NJ, Pollack IF (2015) Outcome and prognostic factors for children with supratentorial primitive neuroectodermal tumors treated with carboplatin during radiotherapy: a report from the Children’s Oncology Group. Pediatr Blood Cancer 62(5):776–783. doi: 10.1002/pbc.25405 CrossRefPubMedPubMedCentralGoogle Scholar
  42. Khaw SL, Coleman LT, Downie PA, Heath JA, Ashley DM (2007) Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer 49(6):808–811. doi: 10.1002/pbc.21270 CrossRefPubMedGoogle Scholar
  43. Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE (2007) Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium study. J Clin Oncol 25(21):3137–3143. doi: 10.1200/JCO.2006.09.4243 CrossRefPubMedGoogle Scholar
  44. Kleinberg LR, Weingart J, Burger P, Carson K, Grossman SA, Li K, Olivi A, Wharam MD, Brem H (2004) Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management. Cancer Investig 22(1):1–9CrossRefGoogle Scholar
  45. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA (2010) Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program. Pediatr Blood Cancer 55(4):668–677. doi: 10.1002/pbc.22576 CrossRefPubMedPubMedCentralGoogle Scholar
  46. Lafay-Cousin L, Mabbott DJ, Halliday W, Taylor MD, Tabori U, Kamaly-Asl ID, Kulkarni AV, Bartels U, Greenberg M, Bouffet E (2010) Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma. J Neurosurg Pediatr 5(6):615–621. doi: 10.3171/2010.3.PEDS09354 CrossRefPubMedGoogle Scholar
  47. Laske DW, Youle RJ, Oldfield EH (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3(12):1362–1368CrossRefPubMedGoogle Scholar
  48. Leonard GD, Fojo T, Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8(5):411–424CrossRefPubMedGoogle Scholar
  49. Lo HW (2010) Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets 10(8):840–848CrossRefPubMedPubMedCentralGoogle Scholar
  50. Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA (2009) Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 10(3):258–266CrossRefPubMedPubMedCentralGoogle Scholar
  51. Middleton MR, Margison GP (2003) Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol 4(1):37–44CrossRefPubMedGoogle Scholar
  52. Murray MJ, Horan G, Lowis S, Nicholson JC (2013) Highlights from the third international central nervous system germ cell tumour symposium: laying the foundations for future consensus. Ecancermedicalscience 7:333. doi: 10.3332/ecancer.2013.333 CrossRefPubMedPubMedCentralGoogle Scholar
  53. Nageswara Rao AA, Scafidi J, Wells EM, Packer RJ (2012) Biologically targeted therapeutics in Pediatric Brain Tumors. Pediatr Neurol 46(4):203–211. doi: 10.1016/j.pediatrneurol.2012.02.005 CrossRefPubMedPubMedCentralGoogle Scholar
  54. Nagpal S (2012) The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma. Neurosurg Clin N Am 23(2):289–295, ix. doi: 10.1016/
  55. Pardridge WM (2007) Blood-brain barrier delivery. Drug Discov Today 12(1–2):54–61. doi: 10.1016/j.drudis.2006.10.013 CrossRefPubMedGoogle Scholar
  56. Partap S, Murphy PA, Vogel H, Barnes PD, Edwards MS, Fisher PG (2011) Liposomal cytarabine for central nervous system embryonal tumors in children and young adults. J Neuro-Oncol 103(3):561–566. doi: 10.1007/s11060-010-0419-y CrossRefGoogle Scholar
  57. Pegg AE (2011) Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. Chem Res Toxicol 24(5):618–639. doi: 10.1021/tx200031q CrossRefPubMedPubMedCentralGoogle Scholar
  58. Piha-Paul SA, Shin SJ, Vats T, Guha-Thakurta N, Aaron J, Rytting M, Kleinerman E, Kurzrock R (2014) Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. Anticancer Res 34(4):1939–1945PubMedGoogle Scholar
  59. Pollack IF, Stewart CF, Kocak M, Poussaint TY, Broniscer A, Banerjee A, Douglas JG, Kun LE, Boyett JM, Geyer JR (2011) A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro-Oncology 13(3):290–297. doi: 10.1093/neuonc/noq199 CrossRefPubMedPubMedCentralGoogle Scholar
  60. Qaddoumi I, Kocak M, Pai Panandiker AS, Armstrong GT, Wetmore C, Crawford JR, Lin T, Boyett JM, Kun LE, Boop FA, Merchant TE, Ellison DW, Gajjar A, Broniscer A (2014) Phase II trial of Erlotinib during and after radiotherapy in children with newly diagnosed high-grade Gliomas. Front Oncol 4:67. doi: 10.3389/fonc.2014.00067 CrossRefPubMedPubMedCentralGoogle Scholar
  61. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE 2nd, Bigner DD, Friedman HS (2002) Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20(9):2277–2283CrossRefPubMedGoogle Scholar
  62. Reed E, Dabholkar M, Chabner BA (1996) Platinum analogues. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy principles and practice. Lippincott-Raven, Philadelphia, pp 357–358Google Scholar
  63. Robinson GW, Orr BA, Gajjar A (2014) Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. BMC Cancer 14:258. doi: 10.1186/1471-2407-14-258 CrossRefPubMedPubMedCentralGoogle Scholar
  64. Robison NJ, Campigotto F, Chi SN, Manley PE, Turner CD, Zimmerman MA, Chordas CA, Werger AM, Allen JC, Goldman S, Rubin JB, Isakoff MS, Pan WJ, Khatib ZA, Comito MA, Bendel AE, Pietrantonio JB, Kondrat L, Hubbs SM, Neuberg DS, Kieran MW (2014) A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer 61(4):636–642. doi: 10.1002/pbc.24794 CrossRefPubMedGoogle Scholar
  65. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397–405. doi: 10.1007/s00401-011-0802-6 CrossRefPubMedGoogle Scholar
  66. Schneider E, Paul D, Ivy P, Cowan KH (1999) Multidrug resistance. Cancer Chemother Biol Response Modif 18:152–177PubMedGoogle Scholar
  67. Skrypek M, Foreman N, Guillaume D, Moertel C (2014) Pilomyxoid astrocytoma treated successfully with vemurafenib. Pediatr Blood Cancer 61(11):2099–2100. doi: 10.1002/pbc.25084 CrossRefPubMedGoogle Scholar
  68. Sposto R, Ertel IJ, Jenkin RD, Boesel CP, Venes JL, Ortega JA, Evans AE, Wara W, Hammond D (1989) The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neuro-Oncol 7(2):165–177CrossRefGoogle Scholar
  69. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20(5):1375–1382CrossRefPubMedGoogle Scholar
  70. Tarbell NJ, Friedman H, Polkinghorn WR, Yock T, Zhou T, Chen Z, Burger P, Barnes P, Kun L (2013) High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol 31(23):2936–2941. doi: 10.1200/JCO.2012.43.9984 CrossRefPubMedPubMedCentralGoogle Scholar
  71. Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, Lucraft H, Gilbertson R, Tait DM, Walker DA, Pizer BL, Imeson J, Lashford LS, International Society of Paediatric O, United Kingdom Children’s Cancer Study G (2003) Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 study. J Clin Oncol 21(8):1581–1591. doi: 10.1200/JCO.2003.05.116 CrossRefPubMedGoogle Scholar
  72. Tishler DM, Weinberg KI, Sender LS, Nolta JA, Raffel C (1992) Multidrug resistance gene expression in pediatric primitive neuroectodermal tumors of the central nervous system. J Neurosurg 76(3):507–512. doi: 10.3171/jns.1992.76.3.0507 CrossRefPubMedGoogle Scholar
  73. Valera ET, de Freitas Cortez MA, de Paula Queiroz RG, de Oliveira FM, Brassesco MS, Jabado N, Faury D, Bobola MS, Machado HR, Scrideli CA, Tone LG (2009) Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine. Childs Nerv Syst 25(1):39–45. doi: 10.1007/s00381-008-0740-3 CrossRefPubMedGoogle Scholar
  74. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T (1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41(1):44–48; discussion 48–49CrossRefPubMedGoogle Scholar
  75. Venkatramani R, Ji L, Lasky J, Haley K, Judkins A, Zhou S, Sposto R, Olshefski R, Garvin J, Tekautz T, Kennedy G, Rassekh SR, Moore T, Gardner S, Allen J, Shore R, Moertel C, Atlas M, Dhall G, Finlay J (2013) Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial. J Neuro-Oncol 113(2):285–291. doi: 10.1007/s11060-013-1111-9 CrossRefGoogle Scholar
  76. Veringa SJ, Biesmans D, van Vuurden DG, Jansen MH, Wedekind LE, Horsman I, Wesseling P, Vandertop WP, Noske DP, Kaspers GJ, Hulleman E (2013) In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS One 8(4):e61512. doi: 10.1371/journal.pone.0061512 CrossRefPubMedPubMedCentralGoogle Scholar
  77. Warren K, Jakacki R, Widemann B, Aikin A, Libucha M, Packer R, Vezina G, Reaman G, Shaw D, Krailo M, Osborne C, Cehelsky J, Caldwell D, Stanwood J, Steinberg SM, Balis FM (2006) Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children’s Oncology Group. Cancer Chemother Pharmacol 58(3):343–347. doi: 10.1007/s00280-005-0172-7 CrossRefPubMedGoogle Scholar
  78. Warren KE, Gururangan S, Geyer JR, McLendon RE, Poussaint TY, Wallace D, Balis FM, Berg SL, Packer RJ, Goldman S, Minturn JE, Pollack IF, Boyett JM, Kun LE (2012) A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J Neuro-Oncol 106(3):643–649. doi: 10.1007/s11060-011-0709-z CrossRefGoogle Scholar
  79. Wilkins DE, Heller DP, Raaphorst GP (1993) Inhibition of potentially lethal damage recovery by cisplatin in a brain tumor cell line. Anticancer Res 13(6A):2137–2142PubMedGoogle Scholar
  80. Wolff JE, Kramm C, Kortmann RD, Pietsch T, Rutkowski S, Jorch N, Gnekow A, Driever PH (2008) Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neuro-Oncol 90(3):309–314. doi: 10.1007/s11060-008-9662-x CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of PediatricsChildren’s Cancer Hospital, MD Anderson Cancer CenterHoustonUSA

Personalised recommendations